Evidence map›Paper›PMID 32357847›Full record

ArticleBMC nephrology2020

Secondary oxalosis induced by xylitol concurrent with lithium-induced nephrogenic diabetes insipidus: a case report.

Shinobu Takayasu, Aya Kamba, Kazutaka Yoshida, Ken Terui, Yutaka Watanuki, Noriko Ishigame, Satoru Mizushiri, Tetsu Tomita, Kazuhiko Nakamura, Norio Yasui-Furukori and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Xylitol exposure and cardiovascular risk.European heart journal · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shinobu TakayasuDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan. stakayas@hirosaki-u.ac.jp.
Aya KambaDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Kazutaka YoshidaDepartment of Neuropsychiatry, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Ken TeruiDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Yutaka WatanukiDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Noriko IshigameDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Satoru MizushiriDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Tetsu TomitaDepartment of Neuropsychiatry, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Kazuhiko NakamuraDepartment of Neuropsychiatry, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Norio Yasui-FurukoriDepartment of Neuropsychiatry, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
Makoto DaimonDepartment of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine and Hospital, 5 Zaifu-cho, Hirosaki, Aomori, 036-8562, Japan.
Hirosaki University · JPDokkyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundXylitol is an approved food additive that is widely used as a sweetener in many manufactured products. It is also used in pharmaceuticals. Secondary oxalosis resulting from high dietary oxalate has been reported. However, reported cases of oxalosis following xylitol infusion are rare. CASE PRESENTATION: A 39-year-old man with a 16-year history of organic psychiatric disorder was hospitalized for a laparoscopic cholecystectomy because of cholecystolithiasis. He had been treated with several antipsychotics and mood stabilizers, including lithium. The patient had polyuria (> 4000 mL/day) and his serum sodium levels ranged from 150 to 160 mmol/L. Urine osmolality was 141 mOsm/L, while serum arginine vasopressin level was 6.4 pg/mL. The patient was diagnosed with nephrogenic diabetes insipidus (NDI), and lithium was gradually discontinued. Postoperative urine volumes increased further to a maximum of 10,000 mL/day, and up to 10,000 mL/day of 5% xylitol was administered. The patient's consciousness level declined and serum creatinine increased to 4.74 mg/dL. This was followed by coma and metabolic acidosis. After continuous venous hemodiafiltration, serum sodium improved to the upper 140 mmol/L range and serum creatinine decreased to 1.25 mg/dL at discharge. However, polyuria and polydipsia of approximately 4000 mL/day persisted. Renal biopsy showed oxalate crystals and decreased expression of aquaporin-2 (AQP2) in the renal tubules. Urinary AQP2 was undetected. The patient was discharged on day 82 after admission.

conclusionsOur patient was diagnosed with lithium-induced NDI and secondary oxalosis induced by excess xylitol infusion. NDI became apparent perioperatively because of fasting, and an overdose of xylitol infusion led to cerebrorenal oxalosis. Our patient received a maximum xylitol dose of 500 g/day and a total dose of 2925 g. Patients receiving lithium therapy must be closely monitored during the perioperative period, and rehydration therapy using xylitol infusion should be avoided in such cases.

Indexed as

AdultCholecystolithiasisDiabetes Insipidus, NephrogenicHumansHyperoxaluriaLithium CompoundsMaleMental DisordersPerioperative CarePolydipsiaPolyuriaXylitolLithium CompoundsXylitolLithiumNephrogenic diabetes insipidusOxalosisXylitol

Identifiers

PMID32357847
PMCPMC7195762
OpenAlexW3023778645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.